Author of

• 32243

  +

  EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Treatment in the Real World - Support, Survivorship, Systems Research
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32262

    +

    EP1.16-19 - Expected Years of Life Loss and Survival Outcome in Non-Small Cell Lung Cancer Patients in Rajavithi Hospital (Now Available) (ID 1599)

    08:00 - 18:00  |  Author(s): Sudsawat Laohavinij
    • Abstract
    • Slides

    Background
    

    To determine expected years of life loss (EYLL) that was the burden of disease parameter of all stages non-small cell lung cancer (NSCLC) patients, survival outcomes in advanced NSCLC patients and association between clinical prognostic factors and survival outcomes in advanced diseases.

    Method
    

    This retrospective cohort study was conducted by reviewing 305 eligible all stages NSCLC patients treated at Oncology Unit, Department of Medicine, Rajavithi hospital from 2011 to 2015. The iSQoL statistical package was used to evaluate EYLL compared to the reference Thai population. For advanced NSCLC patients, univariate and multivariate analysis were used to determine prognostic factors associated with survival outcomes.

    Result
    

    Total 305 patients were included for EYLL analysis. From survival extrapolation, corresponding EYLL of stage I, II, III, and IV NSCLC patients were 9.20, 15.61, 18.03, 20.23 years, respectively. Male patients had EYLL less than female patients (18.81 years vs 20.70 years). In advanced NSCLC, 261 patients were included in survival and prognostic factors analysis. The median overall survival was 6.08 months. The clinical parameters associated with poor survival outcomes in multivariate analysis were male gender (HR 1.71; p = 0.017), presentation with cough or hemoptysis (HR 1.81; p < 0.001), significant weight loss (HR 1.80; p < 0.001), SVC obstruction (HR 1.98; p = 0.019), pathological fracture (HR 2.16; p = 0.002), symptomatic brain metastasis (HR 2.05; p = 0.005), pericardial metastasis (HR 1.88; p = 0.015), adrenal metastasis (HR 1.58; p = 0.011), and not received palliative chemotherapy (HR 6.18; p < 0.001).

    

    

    Conclusion
    

    Diagnosis and treating patients with NSCLC as early as possible would be save more life-years from 18 – 20 years in advanced disease to 9 – 15 years in early stage disease. In advanced NSCLC patients, palliative chemotherapy was the most important factor related to better survival outcomes.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.